The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Synta Pharmaceuticals Inc.  (SNTA) Trade Now »     Rate SNTA  -  Discuss SNTA  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Major Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
66.5%
Top:
0.0%
Rate SNTA:



SNTA Analysis & Videos »


SNTA: Bull or Bear?

Synta Pharma Proceeds with Clinical Trial Graphic_rating_sell SNTA
Mikerun
73%
 -123.00%
in 265 days

Visit the BioMedReports.com research section to view or download the PDF for Synta Pharma (SNTA) along with other free PDF reports and presentations:
http://biomedreports.com/research.html

Synta Pharma: Price: $1.94; Market Cap (MM): $65.8
Market Perform; Simos Simeonidis, Ph.D. - Senior Biotech Analyst, Rodman & Renshaw

Synta moves forward with investment in Phase I/II trial before GSK decision 

<> <> The News:Synta announced this morning that they have dosed the first patient in an open-label, dose-finding, safety and efficacy Phase I/II study with twice-...
By  Mike Havrilla   (+1.04%  risk: conservative)  03/17/09 Comment


Research Note on Synta Pharma (SNTA) Graphic_rating_sell SNTA
Mikerun
73%
 -0.50%
in 4 days
(closed on 03/17/09)

 

<>
Synta Pharma (SNTA): Price: $1.97; Market Cap (MM): $66.8
Market Perform; Simos Simeonidis, Ph.D.
Senior Biotechnology Analyst
<> http://biomedreports.com/research.html

Synta cuts 42% of workforce; waiting for strategic alternatives guidance

The News: Synta announced today a 42% reduction in its workforce, laying off 90 employees, in an effort to preserve its cash balance, following the failure of the Phase III melanoma trial with Elescomol, the company’s only late stage program.

Our view: This was an anticipated and ...
By  Mike Havrilla   (+1.04%  risk: conservative)  03/13/09 Comment


Healthcare Catalyst Stocks for 1H09 Graphic_rating_buy SNTA
Mikerun
73%
 -72.40%
in 65 days
(closed on 03/13/09)

Healthcare Catalyst Stocks for 1H09

<> Below are four companies I have not written about recently with expected catalysts in the first half of 2009 in the form of FDA decisions or clinical trial results.

FDA Calendar of New Product Decisions

Last Fall, Discovery Labs (DSCO) received word from the FDA that its complete response for Surfaxin was accepted, but the six-month Class II review designation means that the decision date is pushed out to mid-April. DSCO presents a model trade on a pending FDA decision at this time since it will likely enjoy a run-up in ...
By  Mike Havrilla   (+1.04%  risk: conservative)  01/07/09 Comment


Get free stock alert for SNTA:
Your Email Address:


Healthcare Catalyst Stocks for 1H09 Graphic_rating_buy SNTA
Mikerun
73%
 +0.00%
in 0 minute
(closed on 01/07/09)

Healthcare Catalyst Stocks for 1H09

<> Below are four companies I have not written about recently with expected catalysts in the first half of 2009 in the form of FDA decisions or clinical trial results.

FDA Calendar of New Product Decisions

Last Fall, Discovery Labs (DSCO) received word from the FDA that its complete response for Surfaxin was accepted, but the six-month Class II review designation means that the decision date is pushed out to mid-April. DSCO presents a model trade on a pending FDA decision at this time since it will likely enjoy a run-up in ...
By  Mike Havrilla   (+1.04%  risk: conservative)  01/07/09 Comment


Healthcare Catalyst Stocks for 1H09 Graphic_rating_buy SNTA
Mikerun
73%
 +0.00%
in 0 minute
(closed on 01/07/09)

Healthcare Catalyst Stocks for 1H09

<> Below are four companies I have not written about recently with expected catalysts in the first half of 2009 in the form of FDA decisions or clinical trial results.

FDA Calendar of New Product Decisions

Last Fall, Discovery Labs (DSCO) received word from the FDA that its complete response for Surfaxin was accepted, but the six-month Class II review designation means that the decision date is pushed out to mid-April. DSCO presents a model trade on a pending FDA decision at this time since it will likely enjoy a run-up in ...
By  Mike Havrilla   (+1.04%  risk: conservative)  01/07/09 Comment


Will Synta Break A 30-Year Old Record? (Part II) Graphic_rating_buy SNTA
-32.42%
in 585 days

For the first part of this article click here.

<>Synta (SNTA) launched a phase I trial in 2004 for the evaluation of elesclomol in combination with paclitaxel in advanced solid tumors.<!--more--> The trial enrolled 35 highly-pretreated patients, who received paclitaxel in combination with escalating doses of elesclomol. There were two partial responses (5.7%), one patient with kaposi’s sarcoma and another patient with ovarian cancer in addition to 15 patients who achieved stable disease. Because this was a combination trial, there was no way of knowing whether elesclomol had a synergistic ef...
By  Ohad Hammer   (+1.52%  risk: moderate)  04/30/08 Comment





People Bullish on SNTA

schadenfreud
Analyst
N/A
3 mos ago

Ohad Hammer
Tracked Blogger
N/A
about 1 year ago

masterwuh
Analyst
 8 %
over 2 years ago

curry
Analyst
12%
over 2 years ago

Austin O
Analyst
 9 %
over 2 years ago


People Bearish on SNTA

Mikerun
Mike Havrilla
Principal
73%
8 mos ago

ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.44% 381
2 Gerald Greene 18.14 +68.27% 211
3 stockmarketfunding.com 17.66 +25.61% 55
4 akiralegrand 13.47 +14.32% 62
5 anup2104 12.13 +74.42% 40


POPULAR STOCKS
Symbol Company Name Sentiment
CSCO Cisco Systems Inc
SIRI Sirius Satellite Radio Inc
MA MasterCard Inc
GOOG Google Inc
MSFT Microsoft Corp
AAPL Apple Computer Inc

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on SNTA


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About Synta Pharmaceuticals Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch